162 related articles for article (PubMed ID: 18317359)
1. Effect of frequently used chemotherapeutic drugs on cytotoxic activity of human cytotoxic T-lymphocytes.
Markasz L; Skribek H; Uhlin M; Otvos R; Flaberg E; Eksborg S; Olah E; Stuber G; Szekely L
J Immunother; 2008 Apr; 31(3):283-93. PubMed ID: 18317359
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapeutic drugs may be used to enhance the killing efficacy of human tumor antigen peptide-specific CTLs.
Correale P; Del Vecchio MT; La Placa M; Montagnani F; Di Genova G; Savellini GG; Terrosi C; Mannucci S; Giorgi G; Francini G; Cusi MG
J Immunother; 2008; 31(2):132-47. PubMed ID: 18481383
[TBL] [Abstract][Full Text] [Related]
3. Effect of frequently used chemotherapeutic drugs on the cytotoxic activity of human natural killer cells.
Markasz L; Stuber G; Vanherberghen B; Flaberg E; Olah E; Carbone E; Eksborg S; Klein E; Skribek H; Szekely L
Mol Cancer Ther; 2007 Feb; 6(2):644-54. PubMed ID: 17308061
[TBL] [Abstract][Full Text] [Related]
4. Presence of low dose of fludarabine in cultures blocks regulatory T cell expansion and maintains tumor-specific cytotoxic T lymphocyte activity generated with peripheral blood lymphocytes.
Hegde U; Chhabra A; Chattopadhyay S; Das R; Ray S; Chakraborty NG
Pathobiology; 2008; 75(3):200-8. PubMed ID: 18550918
[TBL] [Abstract][Full Text] [Related]
5. Adoptive immunotherapy for pancreatic cancer: cytotoxic T lymphocytes stimulated by the MUC1-expressing human pancreatic cancer cell line YPK-1.
Kawaoka T; Oka M; Takashima M; Ueno T; Yamamoto K; Yahara N; Yoshino S; Hazama S
Oncol Rep; 2008 Jul; 20(1):155-63. PubMed ID: 18575732
[TBL] [Abstract][Full Text] [Related]
6. Cancer chemotherapy: not only a direct cytotoxic effect, but also an adjuvant for antitumor immunity.
Ménard C; Martin F; Apetoh L; Bouyer F; Ghiringhelli F
Cancer Immunol Immunother; 2008 Nov; 57(11):1579-87. PubMed ID: 18369619
[TBL] [Abstract][Full Text] [Related]
7. Modeling the CD8+ T effector to memory transition in adoptive T-cell antitumor immunotherapy.
Rolle CE; Carrio R; Malek TR
Cancer Res; 2008 Apr; 68(8):2984-92. PubMed ID: 18413768
[TBL] [Abstract][Full Text] [Related]
8. Modulation of the in vitro cytotoxicity of seven anticancer drugs by protein synthesis inhibition using sparsomycin.
Zylicz Z; Hofs HP; Wagener DJ; Van Rennes H; Wessels JM; van den Broek LA; Ottenheijm HC
Anticancer Res; 1989; 9(6):1835-40. PubMed ID: 2483308
[TBL] [Abstract][Full Text] [Related]
9. [In vitro induced and expanded Epstein Barr virus-specific cytotoxic T lymphocytes can specifically kill nasopharyngeal carcinoma cells].
Chen LP; Huang JQ; Zhou TC; Zhang SX; Wang JL
Nan Fang Yi Ke Da Xue Xue Bao; 2008 Aug; 28(8):1431-3. PubMed ID: 18753079
[TBL] [Abstract][Full Text] [Related]
10. The duration of TCR/pMHC interactions regulates CTL effector function and tumor-killing capacity.
Riquelme E; Carreño LJ; González PA; Kalergis AM
Eur J Immunol; 2009 Aug; 39(8):2259-69. PubMed ID: 19637198
[TBL] [Abstract][Full Text] [Related]
11. Combination chemotherapy and radiation of human squamous cell carcinoma of the head and neck augments CTL-mediated lysis.
Gelbard A; Garnett CT; Abrams SI; Patel V; Gutkind JS; Palena C; Tsang KY; Schlom J; Hodge JW
Clin Cancer Res; 2006 Mar; 12(6):1897-905. PubMed ID: 16551875
[TBL] [Abstract][Full Text] [Related]
12. Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice.
Ramakrishnan R; Assudani D; Nagaraj S; Hunter T; Cho HI; Antonia S; Altiok S; Celis E; Gabrilovich DI
J Clin Invest; 2010 Apr; 120(4):1111-24. PubMed ID: 20234093
[TBL] [Abstract][Full Text] [Related]
13. Clonal diversity of cytotoxic T lymphocytes that recognize autologous oral squamous cell carcinoma.
Kobayashi J; Hirohashi Y; Torigoe T; Michifuri Y; Yamamoto T; Tamura Y; Kamiguchi K; Miyazaki A; Yamaguchi A; Hariu H; Hiratsuka H; Sato N
Hum Immunol; 2009 Feb; 70(2):89-95. PubMed ID: 19124056
[TBL] [Abstract][Full Text] [Related]
14. Efficient induction of human T-cell leukemia virus-1-specific CTL by chimeric particle without adjuvant as a prophylactic for adult T-cell leukemia.
Kozako T; Fukada K; Hirata S; White Y; Harao M; Nishimura Y; Kino Y; Soeda S; Shimeno H; Lemonnier F; Sonoda S; Arima N
Mol Immunol; 2009 Dec; 47(2-3):606-13. PubMed ID: 19889459
[TBL] [Abstract][Full Text] [Related]
15. Sodium butyrate enhances the cytotoxic effect of antineoplastic drugs in human lymphoblastic T-cells.
dos Santos MP; Schwartsmann G; Roesler R; Brunetto AL; Abujamra AL
Leuk Res; 2009 Feb; 33(2):218-21. PubMed ID: 18692895
[TBL] [Abstract][Full Text] [Related]
16. Modifying interleukin-2 concentrations during culture improves function of T cells for adoptive immunotherapy.
Besser MJ; Schallmach E; Oved K; Treves AJ; Markel G; Reiter Y; Schachter J
Cytotherapy; 2009; 11(2):206-17. PubMed ID: 19148842
[TBL] [Abstract][Full Text] [Related]
17. Adoptive immunotherapy combined with FP treatment for head and neck cancer: An in vitro study.
Nishio-Nagai M; Suzuki S; Yoshikawa K; Ueda R; Kazaoka Y
Int J Oncol; 2017 Nov; 51(5):1471-1481. PubMed ID: 29048671
[TBL] [Abstract][Full Text] [Related]
18. Defining the molecular signature of chemotherapy-mediated lung tumor phenotype modulation and increased susceptibility to T-cell killing.
Gameiro SR; Caballero JA; Hodge JW
Cancer Biother Radiopharm; 2012 Feb; 27(1):23-35. PubMed ID: 22316209
[TBL] [Abstract][Full Text] [Related]
19. HPV16E7 tumor antigen modified by KDEL sequence induce specific cytotoxic T lymphocytes-dependent antitumor immunity.
Yin R; Zheng W; Hao F; Yang XC; Zhong BY; Li QJ
J Dermatol Sci; 2009 Aug; 55(2):116-22. PubMed ID: 19500947
[TBL] [Abstract][Full Text] [Related]
20. Activated CD4+ T cells dramatically enhance chemotherapeutic tumor responses in vitro and in vivo.
Radfar S; Wang Y; Khong HT
J Immunol; 2009 Nov; 183(10):6800-7. PubMed ID: 19846868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
